David Altarac, MD, chief medical officer at Innoviva Specialty Therapeutics, which markets sulbactam-durlobactam in the United States, spoke with Contagion at IDWeek 2026 in Washington, DC, about the guidance update and its implications for CRAB treatment decisions.³

Contagion: The 2026 IDSA guidance makes sulbactam-durlobactam the priority for invasive CRAB infections. What are the key takeaways for clinicians?

David Altarac, MD: Sulbactam-durlobactam, or Xacduro, was approved in the US in 2023 for the treatment of hospital-acquired and ventilator-associated pneumonias due to Acinetobacter infections in adults. Carbapenem-resistant Acinetobacter infections have historically been very difficult to treat, with limited treatment options.

Shortly after approval, IDSA issued its guidance and identified Xacduro, along with a carbapenem, as a preferred treatment for carbapenem-resistant Acinetobacter. The recently updated guidance again identifies Xacduro as a first-line agent, in combination with a carbapenem, as the preferred treatment option for invasive CRAB infections. This represents a shift from relying on limited options toward a therapy designed to address the organism’s resistance mechanism, and is an important advancement in how we make treatment decisions.

Editor’s Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Check out the first episode of the ID Week interview with Altarac:
Zoliflodacin Holds Gonorrhea Cure Rates in Chlamydia Coinfected Patients

REFERENCES:Infectious Diseases Society of America. IDSA 2026 guidance on the treatment of antimicrobial-resistant gram-negative infections. Published July 30, 2026. Accessed October 26, 2026. https://www.idsociety.org/practice-guideline/amr-guidance/Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023;23(9):1072-1084. doi:10.1016/S1473-3099(23)00184-6Innoviva Specialty Therapeutics. Innoviva Specialty Therapeutics announces distribution and licensing agreement with Dr. Reddy’s for XACDURO in select international markets. Published June 16, 2026. Accessed October 26, 2026. https://investor.inva.com/node/21156/pdf